Caris Life Sciences, Inc. 8K

Caris Life Sciences reported record Q2 2026 results, raised 2026 revenue guidance, and announced key product launches, a share repurchase program, and a dual stock exchange listing.

Caris Life Sciences, Inc. reported strong financial results for the quarter ended June 30, 2026, with total revenue up 45% year over year to $263.7 million driven by robust growth in molecular profiling services, improved gross margin to 68%, near break-even net income, positive Adjusted EBITDA of $55.7 million, and positive free cash flow, and the company raised its full-year 2026 revenue guidance to $1.03–$1.04 billion while highlighting launches of several new diagnostic products, a $100 million share repurchase program, and a dual listing on NYSE Texas.

Filing Facts

CIK

2019410

Ticker

CAI

Form

8K

Source Type

fda

Accession

0002019410-26-000053

Alert Tier

7